Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Zydus’ Novel Orally Administered GLP-1 Agonist – ‘ZYOG1’ to treat Diabetes and Obesity Enters Phase I Clinical Trial

June 20, 2010 By Bio-Medicine.Org

AHMEDABAD, India, June 21, 2010 /PRNewswire/ — Zydus Cadila,
a global healthcare provider and one of India’s leading healthcare companies has
received Phase I clinical trial permission from the DCGI for ZYOG1
– a novel GLP-1 agonist. Designed and developed at the Zydus
Research Centre using a unique platform technology, ZYOG1 is a
novel, oral, anti-diabetic molecule.

The new class of anti-diabetic drugs called Glucagon Like
Peptide-1 (GLP -1) agonists came to the fore in May 2005 when the first molecule of this
class was approved by the USFDA. Glucagon Like Peptide-1 agonists
are being used to treat people with type 2 diabetes who have not
been able to control their blood sugar levels with oral medicines.
It is an injectible which acts like the natural hormones in the
body that lowers blood sugar.

ZYOG1 would represent a next generation GLP-1 agents, as it
would not have to be injected but can be taken orally. ZYOG1, when
administered by oral route demonstrated beneficial effects in
preclinical models on glucose reduction, HbA1c reduction and showed
an added benefit of weight loss. Additionally, ZYOG1 has displayed
a differentiated preclinical safety profile with no nausea-like
symptoms in the preclinical studies.

Speaking on the new development, Mr. Pankaj R. Patel, Chairman and Managing
Director, Zydus Cadila, said, “The discovery of the novel oral
GLP-1 agonist, ZYOG1, using our own unique, discovery platform
technology, is a significant achievement for us. This novel
molecule would address unmet medical needs in treating diabetes and
holds promising potential in the anti-diabetic and anti-obesity
market.”

The number of diabetics in

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech